<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Misoprostol: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Misoprostol: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Misoprostol: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11798" href="/d/html/11798.html" rel="external">see "Misoprostol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709091"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Patients who could become pregnant:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Misoprostol administration to women who are pregnant can cause birth defects, abortion, premature birth, or uterine rupture. Uterine rupture has been reported when misoprostol was administered in pregnant women to induce labor or to induce abortion. The risk of uterine rupture increases with advancing gestational ages and with prior uterine surgery, including cesarean delivery. Misoprostol should not be taken by pregnant women to reduce the risk of ulcers induced by NSAIDs.</p>
<p style="text-indent:-2em;margin-left:2em;">Patients must be advised of the abortifacient property and warned not to give the drug to others.</p>
<p style="text-indent:-2em;margin-left:2em;">Misoprostol should not be used for reducing the risk of NSAID-induced ulcers in women of childbearing potential unless the patient is at high risk of complications from gastric ulcers associated with use of the NSAID, or is at high risk of developing gastric ulceration. In such patients, misoprostol may be prescribed if the patient has had a negative serum pregnancy test within 2 weeks prior to beginning therapy; is capable of complying with effective contraceptive measures; has received both oral and written warnings of the hazards of misoprostol, the risk of possible contraception failure, and the danger to other women of childbearing potential if the drug is taken by mistake; and will begin misoprostol only on the second or third day of the next normal menstrual period.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F197188"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cytotec</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F197231"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Prostaglandin</li></ul></div>
<div class="block doa drugH1Div" id="F197192"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bb2c4994-a938-434c-83a1-f118716e4bb2">Cervical ripening and labor induction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cervical ripening and labor induction (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> The safest and most effective regimen has not been established; additional studies are needed. Various routes of administration and doses have been evaluated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34607746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34607746'])">Ref</a></span>). Intravaginal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19623003','lexi-content-ref-32778395','lexi-content-ref-WHO.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19623003','lexi-content-ref-32778395','lexi-content-ref-WHO.3'])">Ref</a></span>) and oral routes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32778395','lexi-content-ref-36725134','lexi-content-ref-WHO.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32778395','lexi-content-ref-36725134','lexi-content-ref-WHO.3'])">Ref</a></span>) are recommended based on currently available data. Buccal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30380580','lexi-content-ref-33617796','lexi-content-ref-31075246','lexi-content-ref-15495088']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30380580','lexi-content-ref-33617796','lexi-content-ref-31075246','lexi-content-ref-15495088'])">Ref</a></span>) and sublingual routes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36189381','lexi-content-ref-15495088','lexi-content-ref-36472645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36189381','lexi-content-ref-15495088','lexi-content-ref-36472645'])">Ref</a></span>) have also been studied.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intravaginal</b> (off-label route): 25 mcg (one-fourth of 100 mcg tablet); may repeat at intervals no more frequent than every 3 to 6 hours; 50 mcg every 6 hours may be used in some cases but may be associated with an increased risk of adverse events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19623003']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19623003'])">Ref</a></span>). Additional regimens have been studied (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36472645','lexi-content-ref-36707858','lexi-content-ref-37401143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36472645','lexi-content-ref-36707858','lexi-content-ref-37401143'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 25 mcg (one-fourth of 100 mcg tablet) every 2 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23433680','lexi-content-ref-35478481','lexi-content-ref-WHO.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23433680','lexi-content-ref-35478481','lexi-content-ref-WHO.3'])">Ref</a></span>) or 20 mcg every 2 hours (by dissolving the tablet to make an oral solution) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36725134']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36725134'])">Ref</a></span>); additional regimens have been studied (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24924489','lexi-content-ref-34155622','lexi-content-ref-36472645','lexi-content-ref-36707858','lexi-content-ref-37401143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24924489','lexi-content-ref-34155622','lexi-content-ref-36472645','lexi-content-ref-36707858','lexi-content-ref-37401143'])">Ref</a></span>). Low oral doses have a lower risk of cesarean delivery or failed vaginal delivery and less hyperstimulation compared to vaginal administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24924489','lexi-content-ref-33345875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24924489','lexi-content-ref-33345875'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3d2c2a26-5978-4b7a-ab46-f1f1b99267cf">Early pregnancy loss</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Early pregnancy loss (off-label use):</b>
<b>Intravaginal</b> (off-label route): Initial dose: 800 mcg in patients &lt;13 weeks' gestation. May repeat with one dose if needed, ≥3 hours after the first dose and typically within 7 days if no response to the initial dose is observed. Consider using in combination with oral mifepristone when mifepristone is available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30157093','lexi-content-ref-29874535','lexi-content-ref-16120856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30157093','lexi-content-ref-29874535','lexi-content-ref-16120856'])">Ref</a></span>). Alternately, misoprostol may be administered buccally or sublingually (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0359a0cb-74c5-455d-9ee3-e124101a492f">Incomplete abortion, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Incomplete abortion, treatment (off-label use): Note:</b> A systematic review suggests additional data may be needed to determine the most effective dose and route of administration. Most available data are for patients &lt;13 weeks' gestation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28138973']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28138973'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 600 mcg as a single dose in patients &lt;14 weeks' gestation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Sublingual (off-label route):</b> 400 mcg as a single dose in patients &lt;14 weeks' gestation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.1'])">Ref</a></span>). Dose may be repeated every 3 hours for patients ≥14 weeks' gestation. Caution should be used in patients with a prior uterine incision; clinical judgement is needed to determine number of doses. Consider the possibility of uterine rupture with advanced gestational age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-WHO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-WHO.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1e280eae-968b-4264-8966-a95bec3faa0d">Nonsteroidal anti-inflammatory drug–induced gastric ulcers, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonsteroidal anti-inflammatory drug–induced gastric ulcers, prevention:</b>
<b>Oral:</b> 200 mcg 4 times daily; if not tolerated, may decrease dose to 100 mcg 4 times daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="62aeceee-be44-43a2-be54-aea16c93cda5">Postpartum hemorrhage</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postpartum hemorrhage (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Misoprostol as adjunctive therapy with oxytocin has been used in high-risk patients; monotherapy is recommended in situations where oxytocin is not available (eg, resource-poor settings). The risk of adverse reactions may be associated with combination therapy, dose, and/or route of administration. Additional data may be necessary to further define the optimal dose and route of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24006033','lexi-content-ref-30569545','lexi-content-ref-31721897','lexi-content-ref-31331275','lexi-content-ref-30865585','lexi-content-ref-15639067','lexi-content-ref-36567097','lexi-content-ref-30291483','lexi-content-ref-26892695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24006033','lexi-content-ref-30569545','lexi-content-ref-31721897','lexi-content-ref-31331275','lexi-content-ref-30865585','lexi-content-ref-15639067','lexi-content-ref-36567097','lexi-content-ref-30291483','lexi-content-ref-26892695'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prevention:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Buccal/sublingual</b> (off-label route): 200 to 400 mcg as a single dose administered immediately after delivery (as adjunctive therapy with oxytocin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15572491','lexi-content-ref-30569545','lexi-content-ref-15902121','lexi-content-ref-26534874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15572491','lexi-content-ref-30569545','lexi-content-ref-15902121','lexi-content-ref-26534874'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 400 to 600 mcg as a single dose administered immediately after delivery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35297039','lexi-content-ref-30865585','lexi-content-ref-WHO.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35297039','lexi-content-ref-30865585','lexi-content-ref-WHO.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 600 to 1,000 mcg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28937571']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28937571'])">Ref</a></span>); when used as adjunctive treatment, lower doses (200 to 400 mcg) may be sufficient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36567097']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36567097'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Rectal</b> (off-label route): 600 to 1,000 mcg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28937571']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28937571'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Sublingual</b> (off-label route): 800 mcg as a single dose. Use caution if a prophylactic dose was already given, especially if adverse events were observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35297039','lexi-content-ref-30865585']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35297039','lexi-content-ref-30865585'])">Ref</a></span>). Dosage ranges of 600 to 1,000 mcg as a single dose have been noted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28937571']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28937571'])">Ref</a></span>), however, lower doses (200 to 400 mcg) may be sufficient as adjunctive therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36567097']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36567097'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0d398fed-42ba-4b8a-b9ec-bb2c3c7b76d5">Termination of intrauterine pregnancy, combination therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Termination of intrauterine pregnancy, combination therapy:</b> Refer to Mifepristone monograph.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="05ba472f-9fb7-42d3-b9c4-8196d6cd68ab">Termination of intrauterine pregnancy, monotherapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Termination of intrauterine pregnancy, monotherapy (off-label use):</b>
<b>Note:</b> Monotherapy may be used when mifepristone is not available; however, misoprostol monotherapy is less effective (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32804884','lexi-content-ref-28643396','lexi-content-ref-WHO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32804884','lexi-content-ref-28643396','lexi-content-ref-WHO.1'])">Ref</a></span>). Vaginal administration should be avoided in patients with bleeding or signs of infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28643396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28643396'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Patients &lt;13 weeks' gestation: 800 mcg sublingually every 3 hours for 2 to 3 doses. Alternately, may be administered vaginally or buccally every 3 to 12 hours for 2 to 3 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28643396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28643396'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Patients 13 to 24 weeks' gestation: 400 mcg vaginally, sublingually, or buccally every 3 hours. May give an additional dose if placenta is not expelled 30 minutes after fetal expulsion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28643396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28643396'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Patients 25 to 26 weeks’ gestation: 200 mcg vaginally, sublingually, or buccally every 4 hours. May give an additional dose if placenta is not expelled 30 minutes after fetal expulsion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28643396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28643396'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Patients 27 to 28 weeks’ gestation: 200 mcg vaginally, sublingually, or buccally every 4 hours. May give an additional dose if placenta is not expelled 30 minutes after fetal expulsion. Data is insufficient to recommend use in patients with a prior cesarean delivery or transmural uterine scar (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28643396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28643396'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Patients &gt;28 weeks’ gestation: 100 mcg vaginally, sublingually, or buccally every 6 hours. May give an additional dose if placenta is not expelled 30 minutes after fetal expulsion. Data is insufficient to recommend use in patients with a prior cesarean delivery or transmural uterine scar (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28643396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28643396'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991855"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Dose adjustment is not routinely needed; however, the dose may be reduced if the recommended dose is not tolerated. It is not known if misoprostol is removed by dialysis.</p></div>
<div class="block doha drugH1Div" id="F50989150"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F15976971"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">
<b>Nonsteroidal anti-inflammatory-induced gastric ulcers, prevention:</b> Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F197158"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Abdominal pain, diarrhea (including severe diarrhea)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation, dyspepsia, flatulence, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, arterial thrombosis, cardiac arrhythmia, chest pain, edema, hypertension, hypotension, increased cardiac enzymes in blood specimen, phlebitis, pulmonary embolism, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, dermatitis, diaphoresis, pallor, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased thirst, loss of libido, weight changes</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Change in appetite, dysgeusia, dysphagia, gastroesophageal reflux disease, gastrointestinal hemorrhage, gastrointestinal infection, gastrointestinal inflammation, gingivitis, increased amylase, rectal disease</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria, glycosuria, gynecological disease (dysmenorrhea, heavy menstrual bleeding, menstrual disease, spotty menstruation, uterine cramps), hematuria, impotence, mastalgia, urinary tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Abnormal white blood cell differential, anemia, increased erythrocyte sedimentation rate, purpuric disease, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatobiliary function, increased serum alkaline phosphatase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, asthenia, body pain, cerebrovascular accident, chills, confusion, depression, dizziness, drowsiness, fatigue, neuropathy, neurosis, pain, rigors</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, back pain, gout, muscle cramps, myalgia, stiffness</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Deafness, otalgia, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, polyuria</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis, bronchospasm, dyspnea, epistaxis, pneumonia, upper respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Genitourinary: Abortion, premature labor</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Uterine rupture</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Abnormal platelet aggregation (Beales 1997), prolonged bleeding time (Beales 1997)</p></div>
<div class="block coi drugH1Div" id="F197171"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to misoprostol, other prostaglandins, or any component of the formulation; pregnancy</p>
<p style="text-indent:-2em;margin-left:2em;">When used for termination of intrauterine pregnancy (additional contraindications): Refer to Mifepristone monograph.</p></div>
<div class="block war drugH1Div" id="F197155"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abortifacient: Patients must be advised of the abortifacient property and warned not to give misoprostol to others.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Termination of pregnancy: Misoprostol is approved for use with mifepristone for termination of pregnancy. Refer to mifepristone warnings, precautions, and contraindications for appropriate use of misoprostol for this indication.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Gastric ulcers: For use only in patients at high risk of complications from gastric ulcers (eg, elderly patients, patients with concomitant diseases) or patients at high risk for developing gastric ulcers (eg, those with a history of ulcers) taking nonsteroidal anti-inflammatory drug (NSAIDs) (including aspirin). Misoprostol must be taken during the duration of NSAID therapy. It is not effective in preventing duodenal ulcers in patients taking NSAIDs.</p></div>
<div class="block foc drugH1Div" id="F197165"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cytotec: 100 mcg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cytotec: 200 mcg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mcg, 200 mcg</p></div>
<div class="block geq drugH1Div" id="F197151"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F197173"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Cytotec Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mcg (per each): $4.79</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mcg (per each): $6.98</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (miSOPROStol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mcg (per each): $0.50 - $0.98</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mcg (per each): $0.76 - $1.43</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867585"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mcg, 200 mcg</p></div>
<div class="block adm drugH1Div" id="F197168"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers, prevention: Administer with food and avoid magnesium-containing antacids (minimizes diarrhea); last dose of the day should be taken at bedtime. Continue therapy through the duration of NSAID therapy. Initiate on the second or third day of a normal menstrual period in patients of reproductive potential.</p>
<p style="text-indent:-2em;margin-left:4em;">Termination of intrauterine pregnancy, combination therapy: Refer to the Mifepristone monograph.</p>
<p style="text-indent:-2em;margin-left:4em;">Cervical ripening and labor induction (off-label uses): Because the recommended doses require breaking of the commercially available tablets, some reports recommend weighing the tablet fragments (for oral or vaginal use) or preparing a solution (for oral use) to ensure accurate dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24924489','lexi-content-ref-WHO.3','lexi-content-ref-12237637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24924489','lexi-content-ref-WHO.3','lexi-content-ref-12237637'])">Ref</a></span>). An oral solution can be made by dissolving 1 misoprostol 100 mcg tablet in 20 mL warm water, providing a concentration of 5 mcg/mL. Use within 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36725134']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36725134'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;margin-top:2em;">Misoprostol is available as an oral tablet. Administration of the tablet via the buccal, sublingual, vaginal, and rectal routes has been evaluated. Each route provides different pharmacokinetic and adverse event profiles which may benefit specific indications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17963768']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17963768'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F49104556"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block use drugH1Div" id="F197167"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonsteroidal anti-inflammatory drug–induced gastric ulcers, prevention:</b> To reduce the risk of nonsteroidal anti-inflammatory drug–induced gastric ulcers in patients at high risk of complications.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Termination of intrauterine pregnancy:</b> Medical termination of intrauterine pregnancy through 70 days' gestation in combination with mifepristone (Mifeprex prescribing information).</p></div>
<div class="block off-label drugH1Div" id="F25469219"><span class="drugH1">Use: Off-Label: Adult</span><p>Cervical ripening and labor induction; Early pregnancy loss; Incomplete abortion; Postpartum hemorrhage (prevention/treatment); Termination of intrauterine pregnancy (monotherapy)</p></div>
<div class="block mst drugH1Div" id="F197238"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cytotec may be confused with Cytoxan</p>
<p style="text-indent:-2em;margin-left:4em;">MiSOPROStol may be confused with metoprolol, miFEPRIStone</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299720"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F197160"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May enhance the adverse/toxic effect of MiSOPROStol. More specifically, concomitant use with magnesium-containing antacids may increase the risk of diarrhea. Management: Avoid concomitant use of misoprostol and magnesium-containing antacids. In patients requiring antacid therapy, employ magnesium-free preparations. Monitor for increased adverse effects (e.g., diarrhea, dehydration).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbetocin: MiSOPROStol may enhance the adverse/toxic effect of Carbetocin. Specifically, Carbetocin oxytocic effects may be enhanced. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxytocin: MiSOPROStol may enhance the adverse/toxic effect of Oxytocin. Specifically, oxytocic effects may be enhanced.  Management: The manufacturer of misoprostol recommends avoiding concomitant use with oxytocin.  Misoprostol may augment effects of oxytocin, particularly when given within 4 hours of oxytocin initiation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenylbutazone: May enhance the neurotoxic effect of MiSOPROStol. Specifically, the combination may result in headache, dizziness, and transient diplopia.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F197184"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Misoprostol peak serum concentrations may be decreased if taken with food (not clinically significant).</p></div>
<div class="block rep_considerations drugH1Div" id="F49308270"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">
<b>Misoprostol should not be used for reducing the risk of nonsteroidal anti-inflammatory drug (NSAID)-induced ulcers in patients of childbearing potential unless the patient is at high risk of complications from gastric ulcers associated with use of the NSAIDs, or is at high risk of developing gastric ulceration.</b> When needed, misoprostol may be prescribed if the patient has had a negative serum pregnancy test within 2 weeks prior to beginning therapy; is capable of complying with effective contraceptive measures; has received both oral and written warnings of the hazards of misoprostol, the risk of possible contraception failure, and the danger to other patients of childbearing potential if the drug is taken by mistake; and will begin misoprostol only on the second or third day of the next normal menstrual period. Patients must be advised of the abortifacient property and warned not to give the drug to others.</p></div>
<div class="block pri drugH1Div" id="F197174"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Placental transfer of misoprostol acid (the active metabolite of misoprostol) was detected following a single 25 mcg vaginal misoprostol dose for labor induction (de Oliveira Filgueira 2021).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Misoprostol should not be taken by pregnant patients to reduce the risk of ulcers induced by nonsteroidal anti-inflammatory drug;</b> the use of misoprostol for this indication is contraindicated during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Misoprostol administration to pregnant patients may cause birth defects, abortion, or premature birth. </b>Congenital anomalies following first trimester exposure include skull defects, cranial nerve palsies, facial malformations, and limb defects. Misoprostol may produce uterine contractions leading to fetal death, uterine perforation, or abortion. <b>Patients must be advised of the abortifacient property.</b> Uterine tachysystole may occur and progress to uterine tetany; uteroplacental blood flow may be impaired and uterine rupture or amniotic fluid embolism leading to adverse fetal heart changes may occur.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Uterine rupture has been reported when misoprostol was administered in pregnant patients to induce labor or to induce abortion.</b> The risk of uterine rupture increases with advancing gestational age, grand multiparity, and with prior uterine surgery, including cesarean delivery. Uterine activity and fetal status should be monitored in a hospital setting. Misoprostol should not be used in situations where uterotonic drugs are otherwise contraindicated or inappropriate.</p>
<p style="text-indent:0em;margin-top:2em;">Misoprostol is FDA approved for the medical termination of pregnancy of ≤70 days in conjunction with mifepristone (refer to the Mifepristone monograph for details). It is also may be used as monotherapy when mifepristone is not available (ACOG 2020; FIGO [Morris 2017]; WHO 2022). Medical termination of pregnancy is not recommended for patients with chronic adrenal failure, porphyrias, coagulopathy or concurrent anticoagulant therapy, intrauterine device in place, ectopic pregnancy or concurrent long-term corticosteroid therapy (ACOG 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Because misoprostol may induce or augment uterine contractions, it has been used off label as a cervical-ripening agent for induction of labor. Misoprostol should not be used for this purpose during the third trimester in conditions where a spontaneous labor and vaginal delivery would be contraindicated, including patients who have had a prior cesarean delivery or major uterine surgery (because the risk of uterine rupture is increased) (ACOG 2009; ACOG 205 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Misoprostol may be used off-label for the treatment of incomplete abortion (defined as the passage of some but not all products of conception in a patient with an open cervix) (WHO 2022). A systematic review suggests additional data may be needed to determine the most effective misoprostol dose and route of administration (Kim 2017). Misoprostol is also used off-label for the treatment of early pregnancy loss (&lt;13 weeks of gestation), defined as a nonviable, intrauterine pregnancy with either an empty gestational sac or a gestational sac containing an embryo or fetus without fetal heart activity. Use may be considered in patients who do not want to undergo surgical evacuation and who do not show signs of an infection, hemorrhage, severe anemia, or bleeding disorders (ACOG 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Misoprostol is effective for the management of postpartum hemorrhage. Misoprostol as adjunctive therapy with oxytocin has been used off label in high-risk patients; monotherapy is recommended in situations where oxytocin is not available (eg, resource-poor settings). The risk of adverse reactions may be associated with combination therapy (ACOG 2017; FIGO [Escobar 2022]; Gallos 2018; Koch 2019; Morfaw 2019; SOGC [Robinson 2022], Sweed 2018). Various routes of administration have been used for postpartum hemorrhage (buccal, oral, rectal, sublingual, vaginal). Sublingual administration has the highest bioavailability, rapid onset, and a moderate duration of action. Rectal administration has the lowest bioavailability and serum concentrations may not reach clinical significance (SOGC [Robinson 2022]). The oral route produces the most pronounced initial increase in tonus, and rectal and vaginal routes exhibit longer durations of action as compared to oral and sublingual routes (SOGC [Leduc 2018]). Dose-related fever, shivering, nausea, vomiting, and diarrhea are associated with use of misoprostol (FIGO [Escobar 2022]; SOGC [Robinson 2022]). Buccal administration may be associated with lower plasma concentrations and a decreased risk of adverse reactions compared to sublingual administration (Schaff 2005).</p></div>
<div class="block brc drugH1Div" id="F197175"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Misoprostol acid (the active metabolite of misoprostol) is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Peak milk concentrations of misoprostol acid occur within 1 hour after an oral maternal dose and generally decline over 5 hours (Abdel-Aleem 2003; Vogel 2004). The authors of one study suggest taking the maternal dose immediately after a feed; the next feed would be acceptable in 3 to 4 hours (Vogel 2004).</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends that caution be used if administered to patients who are breastfeeding.</p></div>
<div class="block dic drugH1Div" id="F197176"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">When used for the prevention of NSAID-induced ulcers, take with food.</p></div>
<div class="block mop drugH1Div" id="F9660727"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Cervical ripening and labor induction: Fetal heart rate and uterine activity for 4 hours after each vaginal dose and 2 hours after each oral dose (AWHONN [Simpson 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">Early pregnancy loss: Evaluate Rh status; ultrasound or serial serum β-hCG (if ultrasound not available) 1 to 2 weeks after dosing; patient reported symptoms (ACOG 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Postpartum hemorrhage: heart rate, BP, blood loss, temperature (FIGO [Escobar 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">Prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcers: Pregnancy test within 2 weeks prior to therapy in patients who may become pregnant; adequate diagnostic measures in all cases of undiagnosed abnormal vaginal bleeding.</p>
<p style="text-indent:-2em;margin-left:2em;">Termination of intrauterine pregnancy: Refer to Mifepristone monograph.</p></div>
<div class="block pha drugH1Div" id="F197154"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Misoprostol is a synthetic prostaglandin E<sub>1</sub> analog that replaces the protective prostaglandins consumed with prostaglandin-inhibiting therapies (eg, NSAIDs); has been shown to induce uterine contractions</p></div>
<div class="block phk drugH1Div" id="F197170"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Inhibition of gastric acid secretion: 30 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Duration of action: Inhibition of gastric acid secretion: 3 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid and extensive; extensive; food decreases absorption of misoprostol acid</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Misoprostol acid: &lt;90%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; rapid de-esterification to misoprostol acid (active)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Misoprostol acid: 20 to 40 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Misoprostol acid: Fasting: 12 ± 3 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (80%)</p></div>
<div class="block phksp drugH1Div" id="F51159623"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: C<sub>max</sub>, AUC, and t<sub>½</sub> are almost doubled, but no clear correlation between degree of impairment and AUC is shown.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: AUC is increased in patients &gt;64 years of age.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F197177"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo-misoprostol | Cytotec</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cytotec | Misop | Misoprost beta</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Angusta | Cyprostol | Topogyne</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cytotec | Gymiso</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Cytomis | Indula | Miptol | Misoclear | Misopa | Misotab</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Angusta | Cytotec</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Misoclear</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Angusta | Topogyne</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Prostokos</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Angusta | Cytotec | Misoone</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Cytotec</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Misotrol</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Cytotec</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cytil | Cytil fast | Cytil V | Cytotec | Industol | Misoprol | Misopros</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Angusta | Cytotec | Mispregnol</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Angusta | Cytotec | Misoone</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Cytotec</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Cytotec</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Angusta | Cytotec | Topogyne</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Misoprost | Misotac</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cytotec | Glefos | Misofar | Misoone</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Ace miso | Misoprost</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Angusta | Cytotec | Topogyne</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Angusta | Cytotec | Gymiso | Misoone | Misoprostol Dci</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Angusta | Cytotec | Topogyne</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cytotec</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo-misoprostol | Cytotec</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Angusta | Cytotec</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Chromalux | Citrosol | Cytotec | Gastrul | Invitec | Mipros | Noprostol | Protecid</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Angusta | Cytotec | Misoone</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Cytotec</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cervisure | Contrapill duo | Cytolog | Emrid | Emtee | Kontrac | M Prost | Mesopil | Miso gyn | Misogen | Misogest | Misogon | Misolast | Misolog | Misolup | Misoprost | Mizolast | Pregclear | Prestakind | Rpitant | Zitotec</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Angusta | Cytotec | Misodex | Misoone</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Cytotec</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cytotec</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Cytotec | Isovent | Kontrac | Miso kare | Misoclear | Misoprost</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alsoben | Cirotec | Cystol | Cytotec | Gastec | Gasteck | Gastotec | Gistol | Misel | Misell | Misodol | Misoplus | Mistoren | Nelson misoprostol | Sintec</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Cytotec | Misofar | Misotac</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cytotec | Miso kare</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Cytotec</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Angusta | Cytotec | Gymiso</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Cytotec</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Apostecsol | Cyrux | Cytotec | Misoprostol Serral | Myspess | Taneciprol | Tomispral</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cytotec</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Bleor misoprostol | Chazmax misoprostol | Cytopros | Cytotec | Misoprost | Mistol | Mysotac | Prolon | Texyto</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Angusta | Cytotec</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Angusta | Cytotec | Topogyne</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Cytotec</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Citoprox | Cytofine | Cytotec | Misoprolen | Misoprosmek | Mystol | Prostokos | Tolprax</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Breeky | Cytolog | Cytotol | Liskotol | Mesopil | Miso | Misoclear | Misort | Misotal | Misotin | Mite | S T Mom | Tecmiso | U mol | Zivus</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Angusta | Cytotec</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cytotec</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cytotec | Misofar</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Ovupros</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Cytotec</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Topogyne</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cytotec | Mirolut | Topogin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Cytotec</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Angusta | Cytotec | Topogyne</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Cytotec</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Angusta | Topogyne</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Angusta | Cytotec | Mispregnol</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Misomife</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cytotec | Misoprostol stada</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cytotec</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cytotec</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cytotec | U-miso</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Gastrotec | Mirolut | Misostol | Misotab</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Cytotec | Kontrac | Miso kare | Misoclear | Misofree | Misopro | Misoprost</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Cytotec | Partum</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cytotec</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Heraprostol</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Ace miso | Cytotec</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Cytotec | Kontrac | L pill | Misoclear | Misoprost | Misotac</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Celprotec | Cytotec | Misoclear | Misoprost</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12694965">
<a name="12694965"></a>Abdel-Aleem H, Villar J, Gülmezoglu AM, et al. The pharmacokinetics of the prostaglandin E1 analogue misoprostol in plasma and colostrum after postpartum oral administration. <i>Eur J Obstet Gynecol Reprod Biol</i>. 2003;108(1):25-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/12694965/pubmed" id="12694965" target="_blank">12694965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32635921">
<a name="32635921"></a>Abubeker FA, Lavelanet A, Rodriguez MI, Kim C. Medical termination for pregnancy in early first trimester (≤ 63 days) using combination of mifepristone and misoprostol or misoprostol alone: a systematic review. <i>BMC Womens Health</i>. 2020;20(1):142. doi:10.1186/s12905-020-01003-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/32635921/pubmed" id="32635921" target="_blank">32635921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24924489">
<a name="24924489"></a>Alfirevic Z, Aflaifel N, Weeks A. Oral misoprostol for induction of labour. <i>Cochrane Database Syst Rev.</i> 2014;(6):CD001338. doi:10.1002/14651858.CD001338.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/24924489/pubmed" id="24924489" target="_blank">24924489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30157093">
<a name="30157093"></a>American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 200: early pregnancy loss. <i>Obstet Gynecol</i>. 2018;132(5):e197-e207. doi: 10.1097/AOG.0000000000002899.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/30157093/pubmed" id="30157093" target="_blank">30157093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28937571">
<a name="28937571"></a>American College of Obstetricians and Gynecologists (ACOG). Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 183: Postpartum hemorrhage. <i>Obstet Gynecol.</i> 2017;130(4):e168-e186. doi:10.1097/AOG.0000000000002351.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/28937571/pubmed" id="28937571" target="_blank">28937571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19623003">
<a name="19623003"></a>American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 107: Induction of Labor. <i>Obstet Gynecol</i>. 2009;114(2, pt 1):386-397. doi:10.1097/AOG.0b013e3181b48ef5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/19623003/pubmed" id="19623003" target="_blank">19623003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30681543">
<a name="30681543"></a>American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 205: Vaginal birth after cesarean delivery. <i>Obstet Gynecol</i>. 2019;133(2):e110-e127. doi: 10.1097/AOG.0000000000003078.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/30681543/pubmed" id="30681543" target="_blank">30681543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32804884">
<a name="32804884"></a>American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology, Society of Family Planning. Medication abortion up to 70 days of gestation: ACOG Practice Bulletin, Number 225. <i>Obstet Gynecol</i>. 2020;136(4):e31-e47. doi:10.1097/AOG.0000000000004082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/32804884/pubmed" id="32804884" target="_blank">32804884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36189381">
<a name="36189381"></a>Amini M, Wide-Swensson D, Herbst A. Sublingual misoprostol vs. oral misoprostol solution for induction of labor: a retrospective study. <i>Front Surg</i>. 2022;9:968372. doi:10.3389/fsurg.2022.968372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/36189381/pubmed" id="36189381" target="_blank">36189381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9031907">
<a name="9031907"></a>Beales IL, Clemons M, Kong WM. Misoprostol-associated platelet aggregation dysfunction and increased gastrointestinal blood loss. <i>Eur J Gastroenterol Hepatol</i>. 1997;9(1):91-92. doi:10.1097/00042737-199701000-00021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/9031907/pubmed" id="9031907" target="_blank">9031907</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33345875">
<a name="33345875"></a>Berghella V, Bellussi F, Schoen CN. Evidence-based labor management: induction of labor (part 2).<i> Am J Obstet Gynecol MFM</i>. 2020;2(3):100136. doi:10.1016/j.ajogmf.2020.100136<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/33345875/pubmed" id="33345875" target="_blank">33345875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15572491">
<a name="15572491"></a>Bhullar A, Carlan SJ, Hamm J, Lamberty N, White L, Richichi K. Buccal misoprostol to decrease blood loss after vaginal delivery: a randomized trial. <i>Obstet Gynecol</i>. 2004;104(6):1282‐1288. doi:10.1097/01.AOG.0000144119.94565.18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/15572491/pubmed" id="15572491" target="_blank">15572491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24006033">
<a name="24006033"></a>Bohlmann MK, Rath W. Medical prevention and treatment of postpartum hemorrhage: a comparison of different guidelines. <i>Arch Gynecol Obstet.</i> 2014;289(3):555-567. doi: 10.1007/s00404-013-3016-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/24006033/pubmed" id="24006033" target="_blank">24006033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26538408">
<a name="26538408"></a>Chen W, Xue J, Peprah MK, et al. A systematic review and network meta-analysis comparing the use of Foley catheters, misoprostol, and dinoprostone for cervical ripening in the induction of labour. <i>BJOG.</i> 2016;123(3):346-354. doi:10.1111/1471-0528<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/26538408/pubmed" id="26538408" target="_blank">26538408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32853559">
<a name="32853559"></a>Chu JJ, Devall AJ, Beeson LE, et al. Mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage (MifeMiso): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i>. 2020;396(10253):770-778. doi:10.1016/S0140-6736(20)31788-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/32853559/pubmed" id="32853559" target="_blank">32853559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3133753">
<a name="3133753"></a>Cleghorn GJ, Shepherd RW, Holt TL. The Use of a Synthetic Prostaglandin E1 Analogue (Misoprostol) as an Adjunct to Pancreatic Enzyme Replacement in Cystic Fibrosis. <i>Scand J Gastroenterol Suppl</i>. 1988;143:142-147.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/3133753/pubmed" id="3133753" target="_blank">3133753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cytotec.1">
<a name="Cytotec.1"></a>Cytotec (misoprostol) [prescribing information]. New York, NY: Pfizer; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34022668">
<a name="34022668"></a>de Oliveira Filgueira GC, de Fátima Pinto Rodrigues G, Benzi JRL, et al. Determination of misoprostol acid in plasma samples by UPLC-MS/MS with application in a maternal-fetal pharmacokinetic study following a low misoprostol dose vaginally to induce labor. <i>J Pharm Biomed Anal</i>. 2021;202:114138. doi:10.1016/j.jpba.2021.114138<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/34022668/pubmed" id="34022668" target="_blank">34022668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30380580">
<a name="30380580"></a>Dorr ML, Pierson RC, Daggy J, Quinney SK, Haas DM. Buccal versus vaginal misoprostol for term induction of labor: a retrospective cohort study. <i>Am J Perinatol.</i> 2019;36(7):765-772. doi:10.1055/s-0038-1675219<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/30380580/pubmed" id="30380580" target="_blank">30380580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35297039">
<a name="35297039"></a>Escobar MF, Nassar AH, Theron G, et al; FIGO Safe Motherhood and Newborn Health Committee. FIGO recommendations on the management of postpartum hemorrhage 2022. <i>Int J Gynaecol Obstet</i>. 2022;157(suppl 1):3-50. doi:10.1002/ijgo.14116<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/35297039/pubmed" id="35297039" target="_blank">35297039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21872858">
<a name="21872858"></a>FIGO Working Group on Prevention of Unsafe Abortion and its Consequences; International Federation of Gynecology and Obstetrics. The combination of mifepristone and misoprostol for the termination of pregnancy [published correction appears in <i>Int J Gynaecol Obstet.</i> 2011;115(3):332]. <i>Int J Gynaecol Obstet.</i> 2011;115(1):1-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/21872858/pubmed" id="21872858" target="_blank">21872858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30569545">
<a name="30569545"></a>Gallos ID, Papadopoulou A, Man R, et al. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis. <i>Cochrane Database Syst Rev</i>. 2018;12(12):CD011689. doi:10.1002/14651858.CD011689.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/30569545/pubmed" id="30569545" target="_blank">30569545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33617796">
<a name="33617796"></a>Gomez HB, Hoffman MK, Caplan R, Ruhstaller K, Young MHH, Sciscione AC. Buccal vs vaginal misoprostol combined with Foley catheter for cervical ripening at term (the BEGIN trial): a randomized controlled trial. <i>Am J Obstet Gynecol</i>. 2021;224(5):524.e1-524.e8. doi:10.1016/j.ajog.2021.02.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/33617796/pubmed" id="33617796" target="_blank">33617796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31075246">
<a name="31075246"></a>Haas DM, Daggy J, Flannery KM, et al. A comparison of vaginal versus buccal misoprostol for cervical ripening in women for labor induction at term (the IMPROVE trial): a triple-masked randomized controlled trial. <i>Am J Obstet Gynecol.</i> 2019;221(3):259.e1-259.e16. doi:10.1016/j.ajog.2019.04.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/31075246/pubmed" id="31075246" target="_blank">31075246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15902121">
<a name="15902121"></a>Hamm J, Russell Z, Botha T, Carlan SJ, Richichi K. Buccal misoprostol to prevent hemorrhage at cesarean delivery: a randomized study. <i>Am J Obstet Gynecol</i>. 2005;192(5):1404‐1406. doi:10.1016/j.ajog.2004.12.033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/15902121/pubmed" id="15902121" target="_blank">15902121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26534874">
<a name="26534874"></a>Hernández-Castro F, López-Serna N, Treviño-Salinas EM, Soria-López JA, Sordia-Hernández LH, Cárdenas-Estrada E. Randomized double-blind placebo-controlled trial of buccal misoprostol to reduce the need for additional uterotonic drugs during cesarean delivery. <i>Int J Gynaecol Obstet</i>. 2016;132(2):184‐187. doi:10.1016/j.ijgo.2015.06.060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/26534874/pubmed" id="26534874" target="_blank">26534874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34155622">
<a name="34155622"></a>Kerr RS, Kumar N, Williams MJ, et al. Low-dose oral misoprostol for induction of labour. <i>Cochrane Database Syst Rev</i>. 2021;6(6):CD014484. doi:10.1002/14651858.CD014484<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/34155622/pubmed" id="34155622" target="_blank">34155622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28138973">
<a name="28138973"></a>Kim C, Barnard S, Neilson JP, Hickey M, Vazquez JC, Dou L. Medical treatments for incomplete miscarriage. <i>Cochrane Database Syst Rev</i>. 2017;1(1):CD007223. doi:10.1002/14651858.CD007223.pub4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/28138973/pubmed" id="28138973" target="_blank">28138973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31721897">
<a name="31721897"></a>Koch DM, Rattmann YD. Use of misoprostol in the treatment of postpartum hemorrhage: a pharmacoepidemiological approach. <i>Einstein (Sao Paulo)</i>. 2019;18:eAO5029. doi:10.31744/einstein_journal/2020AO5029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/31721897/pubmed" id="31721897" target="_blank">31721897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34607746">
<a name="34607746"></a>Kumar N, Haas DM, Weeks AD. Misoprostol for labour induction.<i> Best Pract Res Clin Obstet Gynaecol.</i> 2021;77:53-63. doi:10.1016/j.bpobgyn.2021.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/34607746/pubmed" id="34607746" target="_blank">34607746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19155909">
<a name="19155909"></a>Kundodyiwa TW, Alfirevic Z, Weeks AD. Low-dose oral misoprostol for induction of labor: a systematic review. <i>Obstet Gynecol.</i> 2009;113(2, pt 1):374-383. doi:10.1097/AOG.0b013e3181945859<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/19155909/pubmed" id="19155909" target="_blank">19155909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30527079">
<a name="30527079"></a>Leduc D, Senikas V, Lalonde AB. No. 235-active management of the third stage of labour: prevention and treatment of postpartum hemorrhage. <i>J Obstet Gynaecol Can</i>. 2018;40(12):e841‐e855. doi:10.1016/j.jogc.2018.09.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/30527079/pubmed" id="30527079" target="_blank">30527079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mifeprex.1">
<a name="Mifeprex.1"></a>Mifeprex (mifepristone) [prescribing information]. New York, NY: Danco Laboratories; October 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31331275">
<a name="31331275"></a>Morfaw F, Fundoh M, Pisoh C, et al. Misoprostol as an adjunct to oxytocin can reduce postpartum-haemorrhage: a propensity score-matched retrospective chart review in Bamenda-Cameroon, 2015-2016. <i>BMC Pregnancy Childbirth</i>. 2019;19(1):257. doi:10.1186/s12884-019-2407-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/31331275/pubmed" id="31331275" target="_blank">31331275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28643396">
<a name="28643396"></a>Morris JL, Winikoff B, Dabash R, et al. FIGO's updated recommendations for misoprostol used alone in gynecology and obstetrics. <i>Int J Gynaecol Obstet</i>. 2017;138(3):363‐366. doi:10.1002/ijgo.12181<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/28643396/pubmed" id="28643396" target="_blank">28643396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30865585">
<a name="30865585"></a>Muñoz M, Stensballe J, Ducloy-Bouthors AS, et al. Patient blood management in obstetrics: prevention and treatment of postpartum haemorrhage. A NATA consensus statement. <i>Blood Transfus</i>. 2019;17(2):112-136. doi:10.2450/2019.0245-18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/30865585/pubmed" id="30865585" target="_blank">30865585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15495088">
<a name="15495088"></a>Muzonzini G, Hofmeyr GJ. Buccal or sublingual misoprostol for cervical ripening and induction of labour. <i>Cochrane Database Syst Rev.</i> 2004;2004(4):CD004221. doi:10.1002/14651858.CD004221.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/15495088/pubmed" id="15495088" target="_blank">15495088</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36472645">
<a name="36472645"></a>Pergialiotis V, Panagiotopoulos M, Constantinou T, et al. Efficacy and safety of oral and sublingual versus vaginal misoprostol for induction of labour: a systematic review and meta-analysis. <i>Arch Gynecol Obstet.</i> 2023;308(3):727-775. doi:10.1007/s00404-022-06867-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/36472645/pubmed" id="36472645" target="_blank">36472645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36707858">
<a name="36707858"></a>Rahimi M, Haghighi L, Baradaran HR, et al. Comparison of the effect of oral and vaginal misoprostol on labor induction: updating a systematic review and meta-analysis of interventional studies. <i>Eur J Med Res.</i> 2023;28(1):51. doi:10.1186/s40001-023-01007-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/36707858/pubmed" id="36707858" target="_blank">36707858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36567097">
<a name="36567097"></a>Robinson D, Basso M, Chan C, Duckitt K, Lett R. Guideline no. 431: postpartum hemorrhage and hemorrhagic shock. <i>J Obstet Gynaecol Can</i>. 2022;44(12):1293-1310.e1. doi:10.1016/j.jogc.2022.10.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/36567097/pubmed" id="36567097" target="_blank">36567097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36725134">
<a name="36725134"></a>Robinson D, Campbell K, Hobson SR, MacDonald WK, Sawchuck D, Wagner B. Guideline no. 432c: induction of labour.<i> J Obstet Gynaecol Can</i>. 2023;45(1):70-77.e3. doi:10.1016/j.jogc.2022.11.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/36725134/pubmed" id="36725134" target="_blank">36725134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2120019">
<a name="2120019"></a>Robinson PJ, Smith AL, Sly PD. Duodenal pH in Cystic Fibrosis and Its Relationship to Fat Malabsorption. <i>Dig Dis Sci</i>. 1990;35(10):1299-1304.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/2120019/pubmed" id="2120019" target="_blank">2120019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15639067">
<a name="15639067"></a>Schaff EA, DiCenzo R, Fielding SL. Comparison of misoprostol plasma concentrations following buccal and sublingual administration. <i>Contraception</i>. 2005;71(1):22‐25. doi:10.1016/j.contraception.2004.06.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/15639067/pubmed" id="15639067" target="_blank">15639067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29874535">
<a name="29874535"></a>Schreiber CA, Creinin MD, Atrio J, et al. Mifepristone pretreatment for the medical management of early pregnancy loss. <i>N Engl J Med</i>. 2018;378(23):2161-2170. doi: 10.1056/NEJMoa1715726.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/29874535/pubmed" id="29874535" target="_blank">29874535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32778395">
<a name="32778395"></a>Simpson KR. Cervical ripening and labor induction and augmentation, 5th edition. <i>Nurs Womens Health.</i> 2020;24(4):S1-S41. doi:10.1016/j.nwh.2020.04.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/32778395/pubmed" id="32778395" target="_blank">32778395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30291483">
<a name="30291483"></a>Sweed MS, El-Saied MM, Abou-Gamrah AE, et al. Rectal vs. sublingual misoprostol before cesarean section: double-blind, three-arm, randomized clinical trial. <i>Arch Gynecol Obstet</i>. 2018;298(6):1115‐1122. doi:10.1007/s00404-018-4894-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/30291483/pubmed" id="30291483" target="_blank">30291483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23433680">
<a name="23433680"></a>Tang J, Kapp N, Dragoman M, et al. WHO recommendations for misoprostol use for obstetric and gynecologic indications.<i> Int J Gynaecol Obstet.</i> 2013;121(2):186-189. doi: 10.1016/j.ijgo.2012.12.009.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/23433680/pubmed" id="23433680" target="_blank">23433680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17963768">
<a name="17963768"></a>Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. <i>Int J Gynaecol Obstet</i>. 2007;99(suppl 2):S160-S167. doi:10.1016/j.ijgo.2007.09.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/17963768/pubmed" id="17963768" target="_blank">17963768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26892695">
<a name="26892695"></a>Ugwu IA, Oluwasola TA, Enabor OO, et al. Randomized controlled trial comparing 200μg and 400μg sublingual misoprostol for prevention of primary postpartum hemorrhage. <i>Int J Gynaecol Obstet.</i> 2016;133(2):173-177. doi: 10.1016/j.ijgo.2015.09.026.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/26892695/pubmed" id="26892695" target="_blank">26892695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15592308">
<a name="15592308"></a>Vogel D, Burkhardt T, Rentsch K, et al. Misoprostol versus methylergometrine: pharmacokinetics in human milk. <i>Am J Obstet Gynecol</i>. 2004;191(6):2168-2173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/15592308/pubmed" id="15592308" target="_blank">15592308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1435885">
<a name="1435885"></a>Walt RP. Misoprostol for the Treatment of Peptic Ulcer and Anti-inflammatory Drug-Induced Gastroduodenal Ulceration. <i>N Engl J Med</i>. 1992;327(22):1575-1580.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/1435885/pubmed" id="1435885" target="_blank">1435885</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35478481">
<a name="35478481"></a>Weeks AD, Lightly K, Mol BW, Frohlich J, Pontefract S, Williams MJ; Royal College of Obstetricians and Gynaecologists. Evaluating misoprostol and mechanical methods for induction of labour: scientific impact paper no. 68 April 2022. <i>BJOG</i>. 2022;129(8):e61-e65. doi:10.1111/1471-0528.17136<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/35478481/pubmed" id="35478481" target="_blank">35478481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32954250">
<a name="32954250"></a>Whitehouse K, Brant A, Fonhus MS, Lavelanet A, Ganatra B. Medical regimens for abortion at 12 weeks and above: a systematic review and meta-analysis. <i>Contracept X</i>. 2020;2:100037. doi:10.1016/j.conx.2020.100037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/32954250/pubmed" id="32954250" target="_blank">32954250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12237637">
<a name="12237637"></a>Williams MC, Tsibris JC, Davis G, Baiano J, O'Brien WF. Dose variation that is associated with approximated one-quarter tablet doses of misoprostol. <i>Am J Obstet Gynecol</i>. 2002;187(3):615-619. doi:10.1067/mob.2002.124959<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/12237637/pubmed" id="12237637" target="_blank">12237637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10454679">
<a name="10454679"></a>Wing DA. Labor Induction With Misoprostol. <i>Am J Obstet Gynecol</i>. 1999;181(2):339-345.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/10454679/pubmed" id="10454679" target="_blank">10454679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). <i>Abortion Care Guideline</i>. World Health Organization; 2022. <a href="https://www.ncbi.nlm.nih.gov/books/NBK578942/" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK578942/</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO) recommendations. Uterotonics for the prevention of postpartum haemorrhage. Published 2018. https://apps.who.int/iris/bitstream/handle/10665/277276/9789241550420-eng.pdf?ua=1. Accessed January 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.3">
<a name="WHO.3"></a>World Health Organization (WHO). WHO recommendations for induction of labour. Published September 6, 2011. https://www.who.int/publications/i/item/9789241501156. Accessed August 29, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37401143">
<a name="37401143"></a>Yenuberi H, Mathews J, George A, et al. The efficacy and safety of 25 μg or 50 μg oral misoprostol versus 25 μg vaginal misoprostol given at 4- or 6-hourly intervals for induction of labour in women at or beyond term with live singleton pregnancies: a systematic review and meta-analysis.<i> Int J Gynaecol Obstet.</i> Published online July 3, 2023. doi:10.1002/ijgo.14970<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/37401143/pubmed" id="37401143" target="_blank">37401143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16120856">
<a name="16120856"></a>Zhang J, Gilles JM, Barnhart K, et al; National Institute of Child Health Human Development (NICHD) Management of Early Pregnancy Failure Trial. A comparison of medical management with misoprostol and surgical management for early pregnancy failure. <i>N Engl J Med</i>. 2005;353(8):761-769. doi: 10.1056/NEJMoa044064.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/misoprostol-drug-information/abstract-text/16120856/pubmed" id="16120856" target="_blank">16120856</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9657 Version 316.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
